Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

TFL vs MOSES Holmium Laser in the En-bloc Resection of Bladder Tumors

NCT: NCT06373419 · TERMINATED

NCT IDNCT06373419
StatusTERMINATED
Start Date2023-10-16
Completion2026-09-28
SponsorThunder Bay Regional Health Research Institute (OTHER)
First posted
Last updated

Brief Summary

The goal of this randomized clinical trial is to determine if there is difference in pathological and clinical outcomes between MOSES and TFL in the transurethral laser enucleation of bladder tumors. The main question it aims to answer is: Is there a difference in pathological and clinical outcomes between MOSES Holmium and Thulium Fiber Laser (TFL) in the transurethral laser enucleation of bladder tumors? Participants will randomized to either TFL of MOSES arm for their bladder resection procedure.

Frequently Asked Questions

What is TFL vs MOSES Holmium Laser in the En-bloc Resection of Bladder Tumors?

TFL vs MOSES Holmium Laser in the En-bloc Resection of Bladder Tumors is a clinical trial registered under NCT06373419. Current status: TERMINATED.

What is the status of NCT06373419?

The current status of NCT06373419 (TFL vs MOSES Holmium Laser in the En-bloc Resection of Bladder Tumors) is: TERMINATED.

When did TFL vs MOSES Holmium Laser in the En-bloc Resection of Bladder Tumors start?

TFL vs MOSES Holmium Laser in the En-bloc Resection of Bladder Tumors started on 2023-10-16.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑